Comparing Outcomes of Systemic Anticoagulant Therapy and Vascular Interventional Therapy in Cerebral Venous Sinus Thrombosis with Concurrent Brain Parenchymal Injury: Biomarker Analysis
Prognostic value of serum caspase-cleaved cytokeratin-18 (CCCK-18), neuron-specific enolase (NSE), S-100β, nerve growth factor (NGF) and CRP, D-Dimer, EPO
Abstract
Introduction: it was to investigate the clinical effectiveness of neurovascular interventional thrombectomy for treating cerebral venous sinus thrombosis (CVST) with concurrent brain parenchymal injury and evaluate Prognostic value of serum caspase-cleaved cytokeratin-18 (CCCK-18), neuron-specific enolase (NSE), S-100β, nerve growth factor (NGF) and CRP, D-Dimer, EPO.
Materials and Methods:Ninety patients with CVST combined with parenchymal brain damage were randomly divided into the systemic anticoagulant therapy group (SAT group) and the vascular interventional therapy group (VIT group), with 45 patients in each group. The SAT group received only systemic anticoagulant therapy, while the VIT group received systemic anticoagulant therapy combined with neuroendovascular thrombectomy. Three months after discharge, mRS, NIHSS, GCS, and patients' quality of life were assessed. Peripheral blood samples were collected to measure changes in CRP, D-Dimer, EPO, and caspase-cleaved cytokeratin-18 (CCCK-18) levels. The levels of serum neuron-specific enolase (NSE), S-100β, and nerve growth factor (NGF) before treatment and at 3 days and 7 days post-treatment were compared.Follow-up at six months post-discharge included calculations of mortality and recanalization rates, as well as evaluations of short-term prognosis.
Results:In the VIT group, the proportion of patients with an mRS ≥ 2 at 3 months post-discharge was 11.1%, compared to 35.6% in the SAT group, indicating a significantly lower proportion in the VIT group (P < 0.05). Additionally, compared to the SAT group, the VIT group had lower NIHSS scores, higher GCS and SF-36 scores, and lower levels of serum CRP, EPO, and CCCK-8 (P < 0.05). The levels of NSE and S-100β in the VIT group at 7 days post-treatment were significantly lower than those in the SAT group (P< 0.05), whereas the NGF levels at 3 days post-treatment were higher in the VIT group compared to the SAT group (P< 0.05).Follow-up revealed that the survival rates in the SAT and VIT groups were 88.9% and 95.6%, respectively (no significant difference). However, the proportion of patients with an mRS ≥ 2 was lower in the VIT group compared to the SAT group (20.0% vs. 42.2%), and the complete recanalization rate was higher in the VIT group (73.3% vs. 53.3%) (both P < 0.05).
Conclusion: combined SAT with neurovascular interventional thrombectomy benefits patients with CVST and concurrent brain parenchymal injury by promoting recovery of neurological deficits and consciousness, achieving vascular recanalization.
References
2. van de Munckhof A, Borhani-Haghighi A, Aaron S, Krzywicka K, van Kammen MS, Cordonnier C, Kleinig TJ, Field TS, Poli S, Lemmens R, Scutelnic A, Lindgren E, Duan J, Arslan Y, van Gorp EC, Kremer Hovinga JA, Günther A, Jood K, Tatlisumak T, Putaala J, Heldner MR, Arnold M, de Sousa DA, Wasay M, Arauz A, Conforto AB, Ferro JM, Coutinho JM; Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group. Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries. International Journal of Stroke: Official Journal of the International Stroke Society, 2023;18(9):1112-1120.
3. Panichpisal K, Ruff I, Singh M, Hamidi M, Salinas PD, Swanson K, Medlin S, Dandapat S, Tepp P, Kuchinsky G, Pesch A, Wolfe T. Cerebral venous sinus thrombosis associated with coronavirus disease 2019: case report and review of the literature. The Neurologist, 2022;27(5):253-262.
4. Liberman AL. Diagnosis and treatment of cerebral venous thrombosis. Continuum (Minneap Minn), 2023;29(2):519-539.
5. Shlobin NA, LoPresti MA, Beestrum M, Lam S. Treatment of pediatric cerebral venous sinus thromboses: the role of anticoagulation. Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery, 2020;36(11):2621-2633.
6. Jedi F, Dethlefs G, Hauser TK, Hennersdorf F, Mengel A, Ernemann U, Bender B. Mechanical thrombectomy in cerebral venous sinus thrombosis: reports of a retrospective single-center study. Journal of Clinical Medicine, 2022;11(21):6381(1-11).
7. Mera Romo WC, Ariza-Varón M, Escobar FN, Castillo AL. Cerebral venous sinus thrombosis treated with vacuum aspiration thrombectomy without thrombolysis: a descriptive and retrospective study of 5 years’ experience at a single center. Journal of Vascular and Interventional Radiology, 2022;33(10):1173-1183.e1.
8. Gadgil N, Aldave G, Whitehead WE, Dmytriw AA, Chen K, Orbach D, Maier I, Behme D, Fargen KM, Elijovich L, Dornbos D 3rd, Spiotta A, Kan P. Endovascular intervention for refractory pediatric cerebral venous sinus thrombosis. Pediatric Neurology, 2021;121:45-50.
9. Jia J, Xi G, Fan W, Wang G, Li J, Huang J. Cerebrovascular intervention therapy worked positively in one patient with severe cerebral venous sinus thrombosis due to hyperthyroidism: a case report and review of the literature. Journal of Medical Case Reports, 2022;16(1):250(1-4).
10. Roeder HJ, Lopez JR, Miller EC. Ischemic stroke and cerebral venous sinus thrombosis in pregnancy. Handbook of Clinical Neurology, 2020;172:3-31.
11. Guo X, Sun J, Lu X, Guan S. Intrasinus thrombolysis for cerebral venous sinus thrombosis: single-center experience. Frontiers in Neurology, 2019;10:1185(1-7).
12. Kalita J, Singh VK, Jain N, Misra UK, Kumar S. Cerebral venous sinus thrombosis score and its correlation with clinical and MRI findings. Journal of Stroke and Cerebrovascular Diseases, 2019;28(11):104324(1-8).
13. Andersen TH, Hansen K, Truelsen T, Cronqvist M, Stavngaard T, Cortsen ME, Holtmannspötter M, Højgaard JLS, Stensballe J, Welling KL, Gutte H. Endovascular treatment for cerebral venous sinus thrombosis - a single center study. British Journal of Neurosurgery, 2021;35(3):259-265.
14. Weimar C, Masuhr F, Hajjar K. Diagnosis and treatment of cerebral venous thrombosis. Expert Review of Cardiovascular Therapy, 2012;10(12):1545-53.
15. El Meskine T, Li J, Reise J, Toffa DH. Epilepsy and cerebral developmental venous anomalies (DVAs): a systematic review. Epileptic Disorders : International Epilepsy Journal with Videotape, 2023;25(2):209-217.
16. Kumral E, Polat F, Uzunköprü C, Callı C, Kitiş Ö. The clinical spectrum of intracerebral hematoma, hemorrhagic infarct, non-hemorrhagic infarct, and non-lesional venous stroke in patients with cerebral sinus-venous thrombosis. European Journal of Neurology, 2012;19(4):537-43.
17. Komro J, Findakly D. Cerebral venous sinus thrombosis in adults with prothrombotic conditions: a systematic review and a case from our institution. Cureus, 2020;12(4):e7654(1-12).
18. Salehi Omran S, Shu L, Chang A, Parikh NS, Zubair AS, Simpkins AN, Heldner MR, Hakim A, Kasab SA, Nguyen T, Klein P, Goldstein ED, Vedovati MC, Paciaroni M, Liebeskind DS, Yaghi S, Cutting S. Timing and predictors of recanalization after anticoagulation in cerebral venous thrombosis. Journal of Stroke, 2023;25(2):291-298.
19. Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, di Minno M, Maino A, Martinelli I, Masuhr F, de Sousa DA, Stam J; European Stroke Organization. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis - Endorsed by the European Academy of Neurology. European Stroke Journal, 2017;2(3):195-221.
20. Hersh DS, Hayman E, Aarabi B, Stein D, Diaz C, Massetti J, Schwartzbauer GT. 175 safety of anticoagulation for the treatment of cerebral venous sinus thrombosis in adult trauma patients. Neurosurgery, 2016;63:169-170.
21. Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database of Systematic Reviews, 2011;2011(8):CD002005(1-18).
22. Paybast S, Mohamadian R, Emami A, Jameie M, Shahrab F, Zamani F, Sharifipour E. Safety and efficacy of endovascular thrombolysis in patients with acute cerebral venous sinus thrombosis: a systematic review. Interventional Neuroradiology : Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences, 2022;15910199221143418(1-13).
23. Yang J, Wang H, Chen Y, Qiu M, Zhang B, Chen Z. Balloon-assisted thrombectomy and intrasinus urokinase thrombolysis for severe cerebral venous sinus thrombosis. Frontiers in Neurology, 2021;12:735540(1-9).
24. Pasarikovski CR, Ku JC, Keith J, Ramjist J, Dobashi Y, Priola SM, da Costa L, Kumar A, Yang VXD. Mechanical thrombectomy and intravascular imaging for cerebral venous sinus thrombosis: a preclinical model. Journal of Neurosurgery, 2020;135:1-6.
25. Li X, Li T, Fan Y. Efficacy of intravascular mechanical thrombectomy combined with thrombolysis and anticoagulant therapy in the treatment of cerebral venous sinus thrombosis and its effect on neurological function and coagulation indices. American Journal of Translational Research, 2021;13(6):6921-6928.
26. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2011;42(4):1158-92.
27. Arac A, Lee M, Steinberg GK, Marcellus M, Marks MP. Efficacy of endovascular stenting in dural venous sinus stenosis for the treatment of idiopathic intracranial hypertension. Neurosurgical Focus, 2009;27(5):E14(1-8).
28. Chen PY, Hu HH, Chang FC, Chern CM. Protein S deficiency associated with progressive loss of vision and intracranial venous sinus thrombosis. Journal of the Chinese Medical Association, 2004;67(10):521-6.
29. Mohammadian R, Sohrabi B, Mansourizadeh R, Mohammadian F, Nazempour A, Farhoudi M, Pashapour A, Taher Aghdam AA, Hashemzadeh A, Pourkakrodi M. Treatment of progressive cerebral sinuses thrombosis with local thrombolysis. Interventional Neuroradiology: Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences, 2012;18(1):89-96.
30. Adachi H, Mineharu Y, Ishikawa T, Imamura H, Yamamoto S, Todo K, Yamagami H, Sakai N. Stenting for acute cerebral venous sinus thrombosis in the superior sagittal sinus. Interventional Neuroradiology, 2015;21(6):719-23.
31. Ou L, Liu HR, Shi XY, Peng C, Zou YJ, Jia JW, Li H, Zhu ZX, Wang YH, Su BM, Lai YQ, Chen MY, Zhu WX, Feng Z, Zhang GM, Yao MC. Terminalia chebula Retz. aqueous extract inhibits the Helicobacter pylori-induced inflammatory response by regulating the inflammasome signaling and ER-stress pathway. Journal of Ethnopharmacology, 2024;320:117428(1-14).
32. Peng C, Feng Z, Ou L, Zou Y, Sang S, Liu H, Zhu W, Gan G, Zhang G, Yao M. Syzygium aromaticum enhances innate immunity by triggering macrophage M1 polarization and alleviates Helicobacter pylori-induced inflammation. Journal of Functional Foods, 2023;107:105626(1-13).
33. Kopp TI, Friis S, Christensen J, Tjønneland A, Vogel U. Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men. Cancer Genetics, 2013;206(7-8):266-78.
34. Alharbi OA, Alahmadi KO. The diagnostic utility of unenhanced computed tomography of the brain and D-dimer levels in acute cerebral venous sinus thrombosis: a quantitative study. Journal of Clinical Imaging Science, 2022;12:15(1-8).
35. Domitrz I, Sadowski A, Domitrz W, Kochanowski J. Cerebral venous and sinus thrombosis diagnosis: preliminary study of clinical picture and D-dimer concentration correlation. Neurologia i Neurochirurgia Polska, 2020;54(1):66-72.
36. Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: beyond erythropoietin. Advances in Therapy, 2021;38(1):52-75.
37. Hemani S, Lane O, Agarwal S, Yu SP, Woodbury A. Systematic review of erythropoietin (EPO) for neuroprotection in human studies. Neurochemical Research, 2021;46(4):732-739.
38. Lorente L, Martín MM, Pérez-Cejas A, Ramos L, Argueso M, Solé-Violán J, Cáceres JJ, Jiménez A, García-Marín V. High serum levels of caspase-cleaved cytokeratin-18 are associated with malignant middle cerebral artery infarction patient mortality. BMC Neurology, 2018;18(1):32(1-6).
39. Lorente L, Martín MM, González-Rivero AF, Argueso M, Ramos L, Solé-Violán J, Cáceres JJ, Jiménez A, Borreguero-León JM. Serum levels of caspase-cleaved cytokeratin-18 in patients with severe traumatic brain injury are associated with mortality: a pilot study. PLoS One 2015;10(3):e0121739(1-10).
40. Sun Y, Wang S, Gan S, Niu X, Yin B, Bai G, Yang X, Jia X, Bai L, Zhang M. Serum neuron-specific enolase levels associated with connectivity alterations in anterior default mode network after mild traumatic brain injury. Journal of Neurotrauma, 2021;38(11):1495-1505.
41. Michetti F, D'Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, Corvino V, Geloso MC. The S100B story: from biomarker to active factor in neural injury. Journal of Neurochemistry, 2019;148(2):168-187.
42. Yin Y, Xiao G, Zhang K, Ying G, Xu H, De Melo BAG, Li S, Liu F, Yetisen AK, Jiang N. Tacrolimus- and Nerve Growth Factor-Treated Allografts for Neural Tissue Regeneration. ACS Chemical Neuroscience, 2019;10(3):1411-1419.
Copyright (c) 2025 Xiangjie Cheng
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.